DAC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
The relationships between India in the days of the British Raj and the United States were thick. Swami Vivekananda promoted Yoga and Vedanta in the United States at the World's Parliament of Religions in Chicago, during the World's Fair in 1893. Mark Twain visited India in 1896 and described it in his travelogue Following the Equator with both revulsion and attraction before concluding that India was the only foreign land he dreamed about or longed to see again. Regarding India, Americans learned more from English writer Rudyard Kipling. Mahatma Gandhi had an important influence on the philosophy of non-violence promoted by American civil rights movement leader Martin Luther King Jr. in the 1950s. Former American Military Officer and later a prominent figure in the spiritual and philosophical movement of Theosophy Henry Steel Olcott, left New York in December 1878 to relocate the headquarters of the Theosophical Society to India. He and the society arrived in Bombay on February 16, 1879. Olcott's objective was to immerse himself in the culture of India, the birthplace of his spiritual inspiration, the Buddha. The Society's headquarters were established at Adyar, Chennai, where Olcott also founded the Adyar Library and Research Centre. He aimed to obtain authentic translations of sacred texts from Buddhist, Hindu, and Zoroastrian religions to provide Westerners with a true understanding of Eastern philosophies, countering Westernized interpretations. Throughout his time in India, Olcott worked tirelessly to bridge the cultural and spiritual gap between East and West.
== History == Paliperidone (as Invega) was approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia in 2006. Paliperidone was approved by the FDA for the treatment of schizoaffective disorder in 2009. The long-acting injectable form of paliperidone, marketed as Invega Sustenna in the US, and Xeplion in the EU, was approved by the FDA in July 2009. It was initially approved in the European Union in 2007, for schizophrenia, the extended release form and use for schizoaffective disorder were approved in the EU in 2010, and extension to use in adolescents older than 15 years old was approved in 2014.
Synthesis: The chemical must be produced within the neuron or be present in it as a precursor molecule. Release and response: When the neuron is activated, the chemical must be released and elicit a response in target cells or neurons. Experimental response: Application of the chemical directly to the target cells should produce the same response observed when the chemical is naturally released from neurons. Removal mechanism: There must be a mechanism in place to remove the neurotransmitter from its site of action once its signaling role is complete. However, given advances in pharmacology, genetics, and chemical neuroanatomy, the term "neurotransmitter" can be applied to chemicals that:
Other companies operating in Turin are Maserati, Lancia, Alfa Romeo, Iveco, Pininfarina, Bertone, Sparco, Italdesign Giugiaro, New Holland, Comau, Magneti Marelli, Graziano Oerlikon, Ghia, Fioravanti (automotive), Rai (national broadcasting company), Banca Investis, FCA Bank, Intesa Sanpaolo, Reale Mutua (finance), Invicta, Kappa, Superga (fashion), Ferrero, Lavazza, Martini & Rossi (food & beverage), Alpitour (hospitality and tourism), TILab (ex-CSELT), and Aurora (pen manufacturer). The city is also well known for its aerospace industry Alenia Aeronautica, Thales Alenia Space and Avio. The International Space Station modules Harmony, Columbus, Tranquility, as well as the Cupola and all MPLMs were produced in Turin. The future European launcher projects beyond Ariane 5 will also be managed from Turin by the new NGL company, a subsidiary of EADS (70%) and Aircraft Division of Leonardo (30%).
Nucleases are enzymes that cut DNA strands by catalyzing the hydrolysis of the phosphodiester bonds. Nucleases that hydrolyse nucleotides from the ends of DNA strands are called exonucleases, while endonucleases cut within strands. The most frequently used nucleases in molecular biology are the restriction endonucleases, which cut DNA at specific sequences. For instance, the EcoRV enzyme shown to the left recognizes the 6-base sequence 5′-GATATC-3′ and makes a cut at the horizontal line. In nature, these enzymes protect bacteria against phage infection by digesting the phage DNA when it enters the bacterial cell, acting as part of the restriction modification system. In technology, these sequence-specific nucleases are used in molecular cloning and DNA fingerprinting. Enzymes called DNA ligases can rejoin cut or broken DNA strands. Ligases are particularly important in lagging strand DNA replication, as they join the short segments of DNA produced at the replication fork into a complete copy of the DNA template. They are also used in DNA repair and genetic recombination.
Sources: en.wikipedia.org
Monoclonal+antibodies at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Antibodypedia, open-access virtual repository publishing data and commentary on any antibodies available to the scientific community. Antibody Purification Handbook Archived 5 December 2008 at the Wayback Machine
== Function == Enteroglucagon is a proglucagon-derived peptide or enteroendocrine cells derived peptide in the small intestine. Preproglucagon undergoes post translational modification to release glucagon-like peptides (GLP-1 and GLP-2) and other molecules derived from L-cells of intestine. GLP-1 is derived from a class of intestinal hormones called incretin and the molecule exists in two forms GLP-1(7-37) and GLP-1(7-36) amide. GLP-1 form of incretin starts circulating in response to a high blood glucose level. Incretin effect is a negative feedback loop between glucose and insulin level, it promotes insulin release from beta cells of pancreas islet and suppresses glucagon when the glucose level is high. In vertebrate mammals, GLP-2 sequences are highly conversed in the intestine. The molecule functions as a part of adaptive response, such that contributes intestinal growth, proliferation effect, intestinal dilation (increases the mucosal blood flow) and reduces the chance of apoptosis.
La Familia Michoacana was a drug cartel based in Michoacán between at least 2006 and 2011. It was formerly allied with the Gulf Cartel and Los Zetas, but split off to become an independent organization. La Familia Michoacana was the first cartel targeted by President Calderón's security strategy, beginning with Operation Michoacán in December 2006. Between 2009 and 2010, joint U.S.–Mexican operations led to the arrest of hundreds of La Familia members and the reported death of founder Nazario Moreno González ("El Más Loco"). The group soon split between the Knights Templar Cartel and a faction led by José de Jesús Méndez Vargas ("El Chango"), who was arrested in 2011, after which authorities declared La Familia dismantled, leaving the Knights Templar as its de facto successor. In February 2010, La Familia allied with the Gulf Cartel against Los Zetas and the Beltrán-Leyva Cartel. La Nueva Familia Michoacana emerged from splinters of La Familia in the early 2010s, rebranding while continuing operations in Michoacán and Guerrero, and clashing with the Jalisco New Generation Cartel.
Van Krevelen diagrams are graphical plots developed by Dirk Willem van Krevelen (chemist and professor of fuel technology at the TU Delft) and used to assess the origin and maturity of kerogen and petroleum. The diagram cross-plots the hydrogen:carbon atomic ratio as a function of the oxygen:carbon atomic ratio. Beginning around 2003, the diagrams are often used to visualize data from mass spectrometry analysis, used for mixtures other than kerogen and petroleum. For example, the diagrams have been used in one analysis of the components in Scotch whiskey, and are used in characterizing Dissolved organic carbon (DOC) in waters and soils
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.